{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:54:55Z","timestamp":1794851695279,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lymph & Co"},{"name":"Lymph & Co"},{"name":"Lymph & Co"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MYD88 is the key signaling adaptor-protein for Toll-like and interleukin-1 receptors. A somatic L265P mutation within the Toll\/interleukin-1 receptor (TIR) domain of MYD88 is found in 90% of Waldenstr\u00f6m macroglobulinemia cases and in a significant subset of diffuse large B-cell lymphomas. MYD88-L265P strongly promotes NF-\u03baB pathway activation, JAK-STAT signaling and lymphoma cell survival. Previous studies have identified other residues of the TIR-domain crucially involved in NF-\u03baB activation, including serine 257 (S257), indicating a potentially important physiological role in the regulation of MYD88 activation. Here, we demonstrate that MYD88 S257 is phosphorylated in B-cell lymphoma cells and that this phosphorylation is required for optimal TLR-induced NF-\u03baB activation. Furthermore, we demonstrate that a phosphomimetic MYD88-S257D mutant promotes MYD88 aggregation, IRAK1 phosphorylation, NF-\u03baB activation and cell growth to a similar extent as the oncogenic L265P mutant. Lastly, we show that expression of MYD88-S257D can rescue cell growth upon silencing of endogenous MYD88-L265P expression in lymphoma cells addicted to oncogenic MYD88 signaling. Our data suggest that the L265P mutation promotes TIR domain homodimerization and NF-\u03baB activation by copying the effect of MY88 phosphorylation at S257, thus providing novel insights into the molecular mechanism underlying the oncogenic activity of MYD88-L265P in B-cell malignancies.<\/jats:p>","DOI":"10.1038\/s41408-023-00896-6","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T02:01:32Z","timestamp":1692324092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll\/interleukin-1 receptor (TIR) domain"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-8835","authenticated-orcid":false,"given":"Marthe","family":"Minderman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildo","family":"Lantermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"van der Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-2289","authenticated-orcid":false,"given":"Arie J.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"van den Biggelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-5109","authenticated-orcid":false,"given":"Marcel","family":"Spaargaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-0939","authenticated-orcid":false,"given":"Steven T.","family":"Pals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"896_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115\u20139.","journal-title":"Nature."},{"key":"896_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.28","volume":"3","author":"W Kraan","year":"2013","unstructured":"Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.","journal-title":"Blood Cancer J"},{"key":"896_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/leu.2013.348","volume":"28","author":"W Kraan","year":"2014","unstructured":"Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28:719\u201320.","journal-title":"Leukemia."},{"key":"896_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2012;367:826\u201333.","journal-title":"N Engl J Med"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869\u201381.","journal-title":"Blood."},{"key":"896_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","volume":"126","author":"I Bonzheim","year":"2015","unstructured":"Bonzheim I, Giese S, Deuter C, Susskind D, Zierhut M, Waizel M, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126:76\u20139.","journal-title":"Blood."},{"key":"896_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","volume":"122","author":"M Montesinos-Rongen","year":"2011","unstructured":"Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011;122:791\u20132.","journal-title":"Acta Neuropathol"},{"key":"896_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37:551\u201368.e14.","journal-title":"Cancer Cell"},{"key":"896_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.str.2015.12.018","volume":"24","author":"L Vyncke","year":"2016","unstructured":"Vyncke L, Bovijn C, Pauwels E, Van Acker T, Ruyssinck E, Burg E, et al. Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions. Structure. 2016;24:437\u201347.","journal-title":"Structure."},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"30210","DOI":"10.1074\/jbc.M113.490946","volume":"288","author":"M Loiarro","year":"2013","unstructured":"Loiarro M, Volpe E, Ruggiero V, Gallo G, Furlan R, Maiorino C, et al. Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells. J Biol Chem. 2013;288:30210\u201322.","journal-title":"J Biol Chem"},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.celrep.2013.01.029","volume":"3","author":"L Xie","year":"2013","unstructured":"Xie L, Liu C, Wang L, Gunawardena HP, Yu Y, Du R, et al. Protein phosphatase 2A catalytic subunit alpha plays a MyD88-dependent, central role in the gene-specific regulation of endotoxin tolerance. Cell Rep. 2013;3:678\u201388.","journal-title":"Cell Rep"},{"key":"896_CR12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","volume":"84","author":"G Koopman","year":"1994","unstructured":"Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415\u201320.","journal-title":"Blood."},{"key":"896_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/1753425918792070","volume":"24","author":"S Nath Neerukonda","year":"2018","unstructured":"Nath Neerukonda S, Mahadev-Bhat S, Aylward B, Johnson C, Charavaryamath C, Arsenault RJ. Kinome analyses of inflammatory responses to swine barn dust extract in human bronchial epithelial and monocyte cell lines. Innate Immun. 2018;24:366\u201381.","journal-title":"Innate Immun"},{"key":"896_CR14","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.celrep.2014.07.036","volume":"8","author":"K Sharma","year":"2014","unstructured":"Sharma K, D\u2019Souza RC, Tyanova S, Schaab C, Wisniewski JR, Cox J, et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser\/Thr-based signaling. Cell Rep. 2014;8:1583\u201394.","journal-title":"Cell Rep"},{"key":"896_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature18003","volume":"534","author":"P Mertins","year":"2016","unstructured":"Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55\u201362.","journal-title":"Nature."},{"key":"896_CR16","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2014-05-573188","volume":"124","author":"M Avbelj","year":"2014","unstructured":"Avbelj M, Wolz OO, Fekonja O, Bencina M, Repic M, Mavri J, et al. Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood. 2014;124:3896\u2013904.","journal-title":"Blood."},{"key":"896_CR17","doi-asserted-by":"publisher","first-page":"28093","DOI":"10.1074\/jbc.M109.004465","volume":"284","author":"M Loiarro","year":"2009","unstructured":"Loiarro M, Gallo G, Fanto N, De Santis R, Carminati P, Ruggiero V, et al. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem. 2009;284:28093\u2013103.","journal-title":"J Biol Chem"},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1074\/jbc.M309251200","volume":"279","author":"C Kollewe","year":"2004","unstructured":"Kollewe C, Mackensen AC, Neumann D, Knop J, Cao P, Li S, et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem. 2004;279:5227\u201336.","journal-title":"J Biol Chem"},{"key":"896_CR19","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122:1222\u201332.","journal-title":"Blood."},{"key":"896_CR20","doi-asserted-by":"publisher","first-page":"15809","DOI":"10.1074\/jbc.C400613200","volume":"280","author":"M Loiarro","year":"2005","unstructured":"Loiarro M, Sette C, Gallo G, Ciacci A, Fanto N, Mastroianni D, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B. J Biol Chem. 2005;280:15809\u201314.","journal-title":"J Biol Chem"},{"key":"896_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-018-0611-7","volume":"16","author":"A O\u2019Carroll","year":"2018","unstructured":"O\u2019Carroll A, Chauvin B, Brown JWP, Meagher A, Coyle J, Schill J, et al. Pathological mutations differentially affect the self-assembly and polymerisation of the innate immune system signalling adaptor molecule MyD88. BMC Biol. 2018;16:149.","journal-title":"BMC Biol"},{"key":"896_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/protein\/gzw033","volume":"29","author":"C Zhan","year":"2016","unstructured":"Zhan C, Qi R, Wei G, Guven-Maiorov E, Nussinov R, Ma B. Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization. Protein Eng Des Sel. 2016;29:347\u201354.","journal-title":"Protein Eng Des Sel."},{"key":"896_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22590-6","volume":"12","author":"MTB Clabbers","year":"2021","unstructured":"Clabbers MTB, Holmes S, Muusse TW, Vajjhala PR, Thygesen SJ, Malde AK, et al. MyD88 TIR domain higher-order assembly interactions revealed by microcrystal electron diffraction and serial femtosecond crystallography. Nat Commun. 2021;12:2578.","journal-title":"Nat Commun"},{"key":"896_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4049\/jimmunol.1600221","volume":"198","author":"L Sun","year":"2017","unstructured":"Sun L, Pham TT, Cornell TT, McDonough KL, McHugh WM, Blatt NB, et al. Myeloid-Specific Gene Deletion of Protein Phosphatase 2A Magnifies MyD88- and TRIF-Dependent Inflammation following Endotoxin Challenge. J Immunol. 2017;198:404\u201316.","journal-title":"J Immunol"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391.","journal-title":"Nature."},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1006\/jmbi.1999.3310","volume":"294","author":"N Blom","year":"1999","unstructured":"Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999;294:1351\u201362.","journal-title":"J Mol Biol"},{"key":"896_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1189\/jlb.1206746","volume":"82","author":"M Loiarro","year":"2007","unstructured":"Loiarro M, Capolunghi F, Fanto N, Gallo G, Campo S, Arseni B, et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007;82:801\u201310.","journal-title":"J Leukoc Biol"},{"key":"896_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep14246","volume":"5","author":"MA Olson","year":"2015","unstructured":"Olson MA, Lee MS, Kissner TL, Alam S, Waugh DS, Saikh KU. Discovery of small molecule inhibitors of MyD88-dependent signaling pathways using a computational screen. Sci Rep. 2015;5:14246.","journal-title":"Sci Rep"},{"key":"896_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14728222.2018.1464139","volume":"22","author":"F Di Padova","year":"2018","unstructured":"Di Padova F, Quesniaux VFJ, Ryffel B. MyD88 as a therapeutic target for inflammatory lung diseases. Expert Opin Ther Targets. 2018;22:401\u20138.","journal-title":"Expert Opin Ther Targets"},{"key":"896_CR30","first-page":"6203","volume":"37","author":"E Shiratori","year":"2017","unstructured":"Shiratori E, Itoh M, Tohda S. MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells. Anticancer Res. 2017;37:6203\u20139.","journal-title":"Anticancer Res"},{"key":"896_CR31","first-page":"1755","volume":"42","author":"X Wang","year":"2019","unstructured":"Wang X, Tan Y, Huang Z, Huang N, Gao M, Zhou F, et al. Disrupting myddosome assembly in diffuse large Bcell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Oncol Rep. 2019;42:1755\u201366.","journal-title":"Oncol Rep"},{"key":"896_CR32","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bjh.14103","volume":"177","author":"X Liu","year":"2017","unstructured":"Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, et al. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017;177:808\u201313.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00896-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00896-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00896-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:02:48Z","timestamp":1700276568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00896-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00896-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}